🔗 Permalink

Inventor profile of:

Eckard Weber

City:

San Diego, California

Country:

United States

Published Applications:

44

Last publication date:

2024-11-07

Top Assignees for applications by Eckard Weber

The entities that hold a legal rights for patent applications filed by inventor Weber Eckard:

OREXIGEN THERAPEUTICS, INC. 7 La Jolla, CA United States
OREXIGEN THERAPEUTICS, INC. 7 San Diego, CA United States
Novalar Pharmaceuticals, Inc. 4 San Diego, CA United States
Nalpropion Pharmaceuticals LLC 3 Brentwood, TN United States
Nalpropion Pharmaceuticals, Inc. 2 Morristown, NJ United States
Cytovia, Inc. 2 San Diego, CA United States
Nalpropion Pharmaceuticals LLC 2 Morristown, NJ United States
Novalar Pharmaceuticals, Inc. 2 , DE United States
Cothera BioScience, Inc. 1 Grand Cayman, Cayman Islands
Naipropion Pharmaceuticals LLC 1 Morristown, NJ United States

Recent patent applications by Weber Eckard

Eckard Weber from San Diego, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-11-07

US20240366513A1

Human necessities

Methods For Administering Weight Loss Medications

#2 | 2023-12-28

US20230414616A1

Human necessities

LINE-1 INHIBITORS TO TREAT DISEASE

#3 | 2023-09-28

US20230301922A1

Human necessities

Layered Pharmaceutical Formulations

#4 | 2023-09-21

US20230293526A1

Human necessities

METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR

#5 | 2022-06-30

US20220202808A1

Human necessities

Compositions For Affecting Weight Loss

#6 | 2020-11-12

US20200352863A1

Human necessities

Methods for administering weight loss medications

#7 | 2020-10-15

US20200323862A1

Human necessities

Treatment of cancer with TG02

#8 | 2019-09-19

US20190282503A1

Human necessities

Methods For Administering Weight Loss Medications

#9 | 2019-07-18

US20190216799A1

Human necessities

Compositions for affecting weight loss

#10 | 2018-12-20

US20180360760A1

Human necessities

Methods for administering weight loss medications

#11 | 2017-01-12

US20170007598A1

Human necessities

Compositions for affecting weight loss

#12 | 2016-11-24

US20160338965A1

Human necessities

LAYERED PHARMACEUTICAL FORMULATIONS

#13 | 2016-07-07

US20160193152A1

Human necessities

METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS

#14 | 2015-06-18

US20150164806A1

Human necessities

LAYERED PHARMACEUTICAL FORMULATIONS

#15 | 2015-05-21

US20150141452A1

Human necessities

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

#16 | 2014-10-30

US20140322318A1

Human necessities

Methods for administering weight loss medications

#17 | 2013-07-11

US20130177602A1

Human necessities

LAYERED PHARMACEUTICAL FORMULATIONS

#18 | 2012-04-19

US20120093889A1

Human necessities

Layered pharmaceutical formulations

#19 | 2012-01-12

US20120010232A1

Human necessities

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

#20 | 2011-03-10

US20110059170A1

Human necessities

Methods for administering weight loss medications

#21 | 2010-11-25

US20100298348A1

Human necessities

Method of Decreasing Ubiquitylated Protein Levels

#22 | 2010-10-21

US20100267763A1

Human necessities

Method of Decreasing Pro-ADAM10 Secretase and/or Beta Secretase Levels

#23 | 2010-10-07

US20100256173A1

Human necessities

Method of Treating Cognitive Impairment

#24 | 2010-07-29

US20100190793A1

Human necessities

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

#25 | 2010-07-01

US20100168135A1

Human necessities

Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment

#26 | 2009-03-19

US20090076023A1

Human necessities

Local Anesthetic Methods and Kits

#27 | 2008-05-20

US10828795

Compositions for affecting weight loss

#28 | 2008-05-15

US20080113026A1

Human necessities

Layered pharmaceutical formulations

#29 | 2008-05-15

US20080110792A1

Human necessities

METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS

#30 | 2007-11-29

US20070275970A1

Human necessities

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

#31 | 2007-11-22

US20070270450A1

Human necessities

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

#32 | 2007-10-11

US20070238672A1

Human necessities

CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS

#33 | 2007-09-18

US10829381

Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof

#34 | 2007-06-12

US10465810

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof

#35 | 2007-05-03

US20070098748A1

Human necessities

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof

#36 | 2006-06-29

US20060142290A1

Human necessities

Compositions for affecting weight loss

#37 | 2006-05-11

US20060100205A1

Human necessities

Compositions for affecting weight loss

#38 | 2006-03-16

US20060058293A1

Human necessities

Combination of bupropion and a second compound for affecting weight loss

#39 | 2005-09-27

US10429095

Dipeptide apoptosis inhibitors and the use thereof

#40 | 2005-09-15

US20050203099A1

Human necessities

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof

#41 | 2005-09-01

US20050192231A1

Chemistry; metallurgy

Dipeptide apoptosis inhibitors and the use thereof

#42 | 2005-07-28

US20050165098A1

Human necessities

Local anesthetic methods and kits

#43 | 2005-07-28

US20050165097A1

Human necessities

Local anesthetic methods and kits

#44 | 2005-03-29

US10155020

Local anesthetic methods and kits

InventorID:

334243 ⎘